StreetInsider.com News Articles

Form 3 BioNexus Gene Lab Corp For: Nov 28 Filed by: FIDELION DIAGNOSTICS PTE. LTD.

Fri, 07 Aug 2026 16:28:00 -0400

si-local-file:///var/storage/secattach/20260807/26891480.html

Form 3 BioNexus Gene Lab Corp For: Nov 28 Filed by: FIDELION DIAGNOSTICS PTE. LTD.

Fri, 07 Aug 2026 16:28:00 -0400

si-local-file:///var/storage/secattach/20260807/26891480.html

Form 3 BioNexus Gene Lab Corp For: Aug 15 Filed by: Tan Lee Su-Leng

Fri, 31 Jul 2026 17:52:00 -0400

si-local-file:///var/storage/secattach/20260731/26851816.html

Form 3 BioNexus Gene Lab Corp For: Aug 15 Filed by: Tan Lee Su-Leng

Fri, 31 Jul 2026 17:52:00 -0400

si-local-file:///var/storage/secattach/20260731/26851816.html

Form 3 BioNexus Gene Lab Corp For: Dec 11 Filed by: Bin Abdul Hamid Muhammad Azrul

Fri, 31 Jul 2026 17:51:00 -0400

si-local-file:///var/storage/secattach/20260731/26851814.html

Form 3 BioNexus Gene Lab Corp For: Dec 11 Filed by: Bin Abdul Hamid Muhammad Azrul

Fri, 31 Jul 2026 17:51:00 -0400

si-local-file:///var/storage/secattach/20260731/26851814.html

Form 3 BioNexus Gene Lab Corp For: Mar 07 Filed by: Yap Chee Keong

Fri, 31 Jul 2026 17:04:00 -0400

si-local-file:///var/storage/secattach/20260731/26851589.html

Form 3 BioNexus Gene Lab Corp For: Mar 07 Filed by: Yap Chee Keong

Fri, 31 Jul 2026 17:04:00 -0400

si-local-file:///var/storage/secattach/20260731/26851589.html

Form 3 BioNexus Gene Lab Corp For: Jun 17 Filed by: Low Jook Yuen

Fri, 31 Jul 2026 17:02:00 -0400

si-local-file:///var/storage/secattach/20260731/26851580.html

Form 3 BioNexus Gene Lab Corp For: Jun 17 Filed by: Low Jook Yuen

Fri, 31 Jul 2026 17:02:00 -0400

si-local-file:///var/storage/secattach/20260731/26851580.html

Form 3 BioNexus Gene Lab Corp For: Jun 17 Filed by: Chong Set Fui

Fri, 31 Jul 2026 17:00:00 -0400

si-local-file:///var/storage/secattach/20260731/26851547.html

Form 3 BioNexus Gene Lab Corp For: Jun 17 Filed by: Chong Set Fui

Fri, 31 Jul 2026 17:00:00 -0400

si-local-file:///var/storage/secattach/20260731/26851547.html

Form 8-K BioNexus Gene Lab Corp For: Jul 28

Tue, 28 Jul 2026 14:31:00 -0400

si-local-file:///var/storage/secattach/20260728/26826077.html

Form 8-K BioNexus Gene Lab Corp For: Jul 28

Tue, 28 Jul 2026 14:31:00 -0400

si-local-file:///var/storage/secattach/20260728/26826077.html

BioNexus Advances VitaGuard™ Southeast Asia Rollout Following China Working Visit

Tue, 28 Jul 2026 09:00:00 -0400

Meetings in Shanghai and Changzhou link VitaGuard's commercial use in China with BioNexus' Southeast Asian plans and Fidelion's international licensing efforts

KUALA LUMPUR, Malaysia, July 28, 2026 (GLOBE NEWSWIRE) -- BioNexus Gene Lab Corp. (Nasdaq: BGLC) ("BioNexus" or the "Company") today announced continued progress toward commercializing the VitaGuard™ molecular residual disease ("MRD") platform in Southeast Asia following a recent working visit to facilities of the Tongshu Gene group ("Tongshu Gene") in Shanghai and Changzhou, China, led by Dr. Muthu Meyyappan, Chief Commercial Officer of Fidelion Diagnostics Pte. Ltd. ("Fidelion"). The visit combined technical planning with meetings at selected Chinese

BioNexus Advances VitaGuard™ Southeast Asia Rollout Following China Working Visit

Tue, 28 Jul 2026 09:00:00 -0400

Meetings in Shanghai and Changzhou link VitaGuard's commercial use in China with BioNexus' Southeast Asian plans and Fidelion's international licensing efforts
KUALA LUMPUR, Malaysia, July 28, 2026 (GLOBE NEWSWIRE) -- BioNexus Gene Lab Corp. (Nasdaq: BGLC) ("BioNexus" or the "Company") today announced continued progress toward commercializing the VitaGuard™ molecular residual disease ("MRD") platform in Southeast Asia following a recent working visit to facilities of the Tongshu Gene group ("Tongshu Gene") in Shanghai and Changzhou, China, led by Dr. Muthu Meyyappan, Chief Commercial Officer of Fidelion Diagnostics Pte. Ltd. ("Fidelion"). The visit combined technical planning with meetings at selected Chinese

BioNexus Advances VitaGuard™ Southeast Asia Rollout Following China Working Visit

Tue, 28 Jul 2026 09:00:00 -0400

Meetings in Shanghai and Changzhou link VitaGuard's commercial use in China with BioNexus' Southeast Asian plans and Fidelion's international licensing efforts
KUALA LUMPUR, Malaysia, July 28, 2026 (GLOBE NEWSWIRE) -- BioNexus Gene Lab Corp. (Nasdaq: BGLC) ("BioNexus" or the "Company") today announced continued progress toward commercializing the VitaGuard™ molecular residual disease ("MRD") platform in Southeast Asia following a recent working visit to facilities of the Tongshu Gene group ("Tongshu Gene") in Shanghai and Changzhou, China, led by Dr. Muthu Meyyappan, Chief Commercial Officer of Fidelion Diagnostics Pte. Ltd. ("Fidelion"). The visit combined technical planning with meetings at selected Chinese

BioNexus Advances VitaGuard™ Southeast Asia Rollout Following China Working Visit

Tue, 28 Jul 2026 09:00:00 -0400

Meetings in Shanghai and Changzhou link VitaGuard's commercial use in China with BioNexus' Southeast Asian plans and Fidelion's international licensing efforts
KUALA LUMPUR, Malaysia, July 28, 2026 (GLOBE NEWSWIRE) -- BioNexus Gene Lab Corp. (Nasdaq: BGLC) ("BioNexus" or the "Company") today announced continued progress toward commercializing the VitaGuard™ molecular residual disease ("MRD") platform in Southeast Asia following a recent working visit to facilities of the Tongshu Gene group ("Tongshu Gene") in Shanghai and Changzhou, China, led by Dr. Muthu Meyyappan, Chief Commercial Officer of Fidelion Diagnostics Pte. Ltd. ("Fidelion"). The visit combined technical planning with meetings at selected Chinese

Form 8-K BioNexus Gene Lab Corp For: May 29

Fri, 05 Jun 2026 09:00:00 -0400
si-local-file:///var/storage/secattach/20260605/26608861.html

Form 8-K BioNexus Gene Lab Corp For: May 29

Fri, 05 Jun 2026 09:00:00 -0400
si-local-file:///var/storage/secattach/20260605/26608861.html

BioNexus Gene Lab Corp. Calls for Malaysia–China Biotechnology Cooperation to Move Beyond Trade into Co-Development

Fri, 29 May 2026 09:00:00 -0400

KUALA LUMPUR, Malaysia, May 29, 2026 (GLOBE NEWSWIRE) -- BioNexus Gene Lab Corp. (Nasdaq: BGLC) (“BioNexus” or the “Company”), a technology-focused company advancing innovation across biotechnology, precision diagnostics, and emerging healthcare platforms, today highlighted its participation in the 2026 China–Malaysia Economic Cooperation Outlook Forum, held on May 21, 2026 at the Mandarin Oriental Hotel in Kuala Lumpur.

The forum, held under the theme “Advancing Biotechnology and Healthcare Collaboration towards a China–Malaysia Community with a Shared Future,” brought together government representatives, industry leaders, investors, healthcare professionals, and experts from Malaysia and China to discuss strategic cooperation across biotechnology,

BioNexus Gene Lab Corp. Calls for Malaysia–China Biotechnology Cooperation to Move Beyond Trade into Co-Development

Fri, 29 May 2026 09:00:00 -0400

KUALA LUMPUR, Malaysia, May 29, 2026 (GLOBE NEWSWIRE) -- BioNexus Gene Lab Corp. (Nasdaq: BGLC) (“BioNexus” or the “Company”), a technology-focused company advancing innovation across biotechnology, precision diagnostics, and emerging healthcare platforms, today highlighted its participation in the 2026 China–Malaysia Economic Cooperation Outlook Forum, held on May 21, 2026 at the Mandarin Oriental Hotel in Kuala Lumpur.

The forum, held under the theme “Advancing Biotechnology and Healthcare Collaboration towards a China–Malaysia Community with a Shared Future,” brought together government representatives, industry leaders, investors, healthcare professionals, and experts from Malaysia and China to discuss strategic cooperation across biotechnology,

BioNexus Gene Lab Corp. Calls for Malaysia–China Biotechnology Cooperation to Move Beyond Trade into Co-Development

Fri, 29 May 2026 09:00:00 -0400

KUALA LUMPUR, Malaysia, May 29, 2026 (GLOBE NEWSWIRE) -- BioNexus Gene Lab Corp. (Nasdaq: BGLC) (“BioNexus” or the “Company”), a technology-focused company advancing innovation across biotechnology, precision diagnostics, and emerging healthcare platforms, today highlighted its participation in the 2026 China–Malaysia Economic Cooperation Outlook Forum, held on May 21, 2026 at the Mandarin Oriental Hotel in Kuala Lumpur.

The forum, held under the theme “Advancing Biotechnology and Healthcare Collaboration towards a China–Malaysia Community with a Shared Future,” brought together government representatives, industry leaders, investors, healthcare professionals, and experts from Malaysia and China to discuss strategic cooperation across biotechnology,

BioNexus Gene Lab Corp. Calls for Malaysia–China Biotechnology Cooperation to Move Beyond Trade into Co-Development

Fri, 29 May 2026 09:00:00 -0400

KUALA LUMPUR, Malaysia, May 29, 2026 (GLOBE NEWSWIRE) -- BioNexus Gene Lab Corp. (Nasdaq: BGLC) (“BioNexus” or the “Company”), a technology-focused company advancing innovation across biotechnology, precision diagnostics, and emerging healthcare platforms, today highlighted its participation in the 2026 China–Malaysia Economic Cooperation Outlook Forum, held on May 21, 2026 at the Mandarin Oriental Hotel in Kuala Lumpur.

The forum, held under the theme “Advancing Biotechnology and Healthcare Collaboration towards a China–Malaysia Community with a Shared Future,” brought together government representatives, industry leaders, investors, healthcare professionals, and experts from Malaysia and China to discuss strategic cooperation across biotechnology,

Form 10-Q BioNexus Gene Lab Corp For: Mar 31

Fri, 15 May 2026 17:16:00 -0400
si-local-file:///var/storage/secattach/20260515/26507846.html